SCHEDULE 13G/A: BML Investment Partners Corrects Significant Stake in ESSA Pharma, Disclosing 9.5% Ownership

BML Investment Partners, L.P. has filed an amended Schedule 13G to correct its beneficial ownership in ESSA Pharma Inc., reporting a 9.5% stake as of December 31, 2024.

Summary

• BML Investment Partners, L.P. filed an Amendment No. 1 to Schedule 13G regarding its ownership in ESSA Pharma Inc.
• The filing corrects previously reported shares and percentage ownership.
• As of December 31, 2024, BML Investment Partners, L.P. beneficially owns 4,221,546 common shares of ESSA Pharma Inc.
• This ownership represents 9.5% of ESSA Pharma Inc.'s common shares.
• BML Investment Partners, L.P. holds shared voting power and shared dispositive power over all 4,221,546 shares.
• The securities were not acquired for the purpose of changing or influencing the control of ESSA Pharma Inc., nor are they held in connection with any transaction having such purpose or effect, other than activities solely related to a nomination under Rule 240.14a-11.
• The reporting person, BML Investment Partners, L.P., is a Delaware limited partnership.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not convey positive or negative sentiment regarding the company's performance or outlook. It is a neutral, compliance-driven filing.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of significant ownership by an investment entity in a publicly traded company, common in the financial industry. It provides transparency regarding large shareholder positions, which is particularly relevant in the biotechnology and pharmaceutical sectors where investor confidence and strategic stakes can influence company trajectory.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant ownership stake held by BML Investment Partners, L.P., which can influence market perception and trading activity. The correction of previous information ensures accurate public records for investors.

Key Dates

Keywords

ESSA Pharma Inc., BML Investment Partners, Schedule 13G, Beneficial Ownership, Common Shares, SEC Filing, Investment, Shareholder, Biotechnology, Pharmaceutical